P/E ratio for Ardelyx (ARDX)
P/E ratio as of April 2024 (TTM): -54.6
According to Ardelyx's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -54.5833. At the end of 2022 the company had a P/E ratio of -5.94.
P/E ratio history for Ardelyx from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -5.94 | 720.45% |
| 2021 | -0.7237 | -88.26% |
| 2020 | -6.16 | 20.69% |
| 2019 | -5.11 | 362.06% |
| 2018 | -1.10 | -77.23% |
| 2017 | -4.85 | -3.28% |
| 2016 | -5.02 | -69.26% |
| 2015 | -16.3 | -84.65% |
| 2014 | -106 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Abbott Laboratories ABT | 35.6 | -165.28% | 🇺🇸 USA |
 Amgen AMGN | 18.7 | -134.19% | 🇺🇸 USA |
 Sanofi SNY | 14.5 | -126.56% | 🇫🇷 France |
 AstraZeneca AZN | 34.5 | -163.25% | 🇬🇧 UK |
 OPKO Health
OPK | -4.63 | -91.52% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.